185 related articles for article (PubMed ID: 37814010)
1. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism.
Encarnación-Rosado J; Sohn ASW; Biancur DE; Lin EY; Osorio-Vasquez V; Rodrick T; González-Baerga D; Zhao E; Yokoyama Y; Simeone DM; Jones DR; Parker SJ; Wild R; Kimmelman AC
Nat Cancer; 2024 Jan; 5(1):85-99. PubMed ID: 37814010
[TBL] [Abstract][Full Text] [Related]
2. DON of Hope: Starving Pancreatic Cancer by Glutamine Antagonism.
Pillai R; Papagiannakopoulous T
Cancer Res; 2024 Feb; 84(3):349-350. PubMed ID: 38117482
[TBL] [Abstract][Full Text] [Related]
3. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma.
Recouvreux MV; Grenier SF; Zhang Y; Esparza E; Lambies G; Galapate CM; Maganti S; Duong-Polk K; Bhullar D; Naeem R; Scott DA; Lowy AM; Tiriac H; Commisso C
Nat Cancer; 2024 Jan; 5(1):100-113. PubMed ID: 37814011
[TBL] [Abstract][Full Text] [Related]
4. Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism.
Sun W; Luan S; Qi C; Tong Q; Yan S; Li H; Zhang Y
Cell Commun Signal; 2019 Aug; 17(1):111. PubMed ID: 31470862
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
De Santis MC; Gozzelino L; Margaria JP; Costamagna A; Ratto E; Gulluni F; Di Gregorio E; Mina E; Lorito N; Bacci M; Lattanzio R; Sala G; Cappello P; Novelli F; Giovannetti E; Vicentini C; Andreani S; Delfino P; Corbo V; Scarpa A; Porporato PE; Morandi A; Hirsch E; Martini M
Gut; 2023 Feb; 72(2):360-371. PubMed ID: 35623884
[TBL] [Abstract][Full Text] [Related]
7. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.
Sharma NS; Gupta VK; Garrido VT; Hadad R; Durden BC; Kesh K; Giri B; Ferrantella A; Dudeja V; Saluja A; Banerjee S
J Clin Invest; 2020 Jan; 130(1):451-465. PubMed ID: 31613799
[TBL] [Abstract][Full Text] [Related]
9. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
[TBL] [Abstract][Full Text] [Related]
10. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone suppresses pancreatic adenocarcinoma cell proliferation by targeting GOT1 to trigger glutamine metabolism reprogramming.
Yang Y; Zheng M; Han F; Shang L; Li M; Gu X; Li H; Chen L
J Mol Med (Berl); 2022 Apr; 100(4):599-612. PubMed ID: 35212782
[TBL] [Abstract][Full Text] [Related]
12. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Yokoyama Y; Estok TM; Wild R
Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
[TBL] [Abstract][Full Text] [Related]
13. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
14. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism.
Biancur DE; Paulo JA; Małachowska B; Quiles Del Rey M; Sousa CM; Wang X; Sohn ASW; Chu GC; Gygi SP; Harper JW; Fendler W; Mancias JD; Kimmelman AC
Nat Commun; 2017 Jul; 8():15965. PubMed ID: 28671190
[TBL] [Abstract][Full Text] [Related]
15. Discovery of GOT1 Inhibitors from a Marine-Derived
Yan S; Qi C; Song W; Xu Q; Gu L; Sun W; Zhang Y
Mar Drugs; 2021 Oct; 19(11):. PubMed ID: 34822459
[TBL] [Abstract][Full Text] [Related]
16. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
[TBL] [Abstract][Full Text] [Related]
17. Novel Liver X Receptor Ligand GAC0001E5 Disrupts Glutamine Metabolism and Induces Oxidative Stress in Pancreatic Cancer Cells.
Srivastava S; Widmann S; Ho C; Nguyen D; Nguyen A; Premaratne A; Gustafsson JÅ; Lin CY
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348693
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth.
Liu H; Zhang H; Liu X; Guo W; Liu Q; Chen L; Pang J; Liu X; Li R; Tong WM; Wu H; Dai M; Liang Z
Cancer Lett; 2023 Feb; 555():216040. PubMed ID: 36565920
[TBL] [Abstract][Full Text] [Related]
19. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
20. Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Zhou G; Yu J; Wang A; Liu SH; Sinnett-Smith J; Wu J; Sanchez R; Nemunaitis J; Ricordi C; Rozengurt E; Brunicardi FC
Curr Mol Med; 2016; 16(1):83-90. PubMed ID: 26695692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
